Back to Search
Start Over
COVID-19 Drug Development.
- Source :
-
Journal of microbiology and biotechnology [J Microbiol Biotechnol] 2022 Jan 28; Vol. 32 (1), pp. 1-5. - Publication Year :
- 2022
-
Abstract
- Diagnostics, vaccines, and drugs are indispensable tools and control measures employed to overcome infectious diseases such as coronavirus disease 2019 (COVID-19). Diagnostic tools based on RT-PCR were developed early in the COVID-19 pandemic and were urgently required for quarantine (testing, tracing and isolation). Vaccines such as mRNA vaccines and virus-vectored vaccines were also successfully developed using new platform technologies within one year after identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of COVID-19. Drug development has been conducted in various ways including drug repurposing, convalescent plasma therapy, and monoclonal antibody development. Among the above efforts, this review examines COVID-19 drug development along with the related and upcoming challenges.
- Subjects :
- Antibodies, Monoclonal therapeutic use
Antibodies, Viral blood
Antiviral Agents chemistry
COVID-19 prevention & control
Humans
Immunization, Passive
SARS-CoV-2 genetics
Antiviral Agents therapeutic use
COVID-19 therapy
Drug Development
Drug Repositioning methods
SARS-CoV-2 drug effects
COVID-19 Drug Treatment
Subjects
Details
- Language :
- English
- ISSN :
- 1738-8872
- Volume :
- 32
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of microbiology and biotechnology
- Publication Type :
- Academic Journal
- Accession number :
- 34866128
- Full Text :
- https://doi.org/10.4014/jmb.2110.10029